Featured Content
Interesting Myeloma Articles September 2021
Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma
Source: Myeloma Research News Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This...
Recent Publications
The role of KIAA1191 in the necroptotic pathway of multiple myeloma
Ann Hematol. 2022 Feb;101(2):359-367. doi: 10.1007/s00277-021-04710-w. Epub 2022 Jan 6. ABSTRACT Multiple myeloma (MM) is an incurable plasma cell malignancy, and International Staging System (ISS) is used to predict the outcomes of MM patients. However, ISS stage is...
Duodenal Ulcer with Massive Gastrointestinal Hemorrhage as an Initial Manifestation in Multiple Myeloma with Extramedullary Disease: A Case Report
Medicina (Kaunas). 2022 Jan 16;58(1):134. doi: 10.3390/medicina58010134. ABSTRACT Plasma cell neoplasms are characterized by dysregulated proliferation of mature B cells, which can present with either single (solitary plasmacytoma) or systemic (multiple myeloma (MM))...
Immunoglobulin M multiple myeloma: a six-case report and literature review
Zhonghua Xue Ye Xue Za Zhi. 2021 Dec 14;42(12):1011-1014. doi: 10.3760/cma.j.issn.0253-2727.2021.12.008. ABSTRACT Objective: To investigate the clinical characteristics, responses, and prognosis of immunoglobulin M multiple myeloma (IgM MM) . Methods: The clinical...
Clinical update-multiple myeloma
Radiologe. 2022 Jan;62(1):3-11. doi: 10.1007/s00117-021-00941-0. Epub 2021 Dec 30. ABSTRACT CLINICAL ISSUE: Multiple myeloma (MM) is a malignancy of hematopoetic system and is associated with destruction of bone, suppressed bone marrow function and renal failure. It...
Non-invasive discrimination of multiple myeloma using label-free serum surface-enhanced Raman scattering spectroscopy in combination with multivariate analysis
Anal Chim Acta. 2022 Jan 25;1191:339296. doi: 10.1016/j.aca.2021.339296. Epub 2021 Nov 17. ABSTRACT We report non-invasive discrimination of multiple myeloma (MM) using label-free serum surface-enhanced Raman scattering (SERS) spectroscopy in combination with...
Pitfalls in Assessing Measurable Residual Disease in Plasma Cell Myeloma: a Comparison between Common Laboratory Tests
Clin Lab. 2022 Jan 1;68(1). doi: 10.7754/Clin.Lab.2021.210454. ABSTRACT BACKGROUND: Measurable residual disease (MRD) in plasma cell myeloma is one of the most important determinants for patients' outcome. Several laboratory tests exist to assess for the presence of...
The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
Cells. 2021 Dec 8;10(12):3464. doi: 10.3390/cells10123464. ABSTRACT Background: Multiple myeloma (MM) remains incurable despite high-dose chemotherapy, autologous stem cell transplants and novel agents. Even with the improved survival of MM patients treated with novel...
Coexistence of plasma cell neoplasia and myelodysplastic syndrome with excess blasts: case reports and literature review
Ann Palliat Med. 2021 Dec;10(12):12431-12440. doi: 10.21037/apm-21-3210. ABSTRACT BACKGROUND: The coexistence of plasma cell neoplasia such as multiple myeloma (MM) or monoclonal gammopathy of underdetermined significance (MGUS) with myeloid neoplasia such as...
